The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Cummings Keith Lamont since 2020.
This trader's CIK number is 1809204.
At the time of last reporting, Cummings Keith Lamont was the Chief Financial Officer of Pliant Therapeutics, Inc.. (stock ticker symbol PLRX).
Also see all insider trading activities at Pliant Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | PLRX | 0 | $0 | 20,148 | $225,677 | 0 | $0 |
| 2024 | PLRX | 0 | $0 | 20,692 | $294,657 | 21,000 | $43,680 |
| 2023 | PLRX | 0 | $0 | 59,731 | $1,670,204 | 66,550 | $200,524 |
| 2022 | PLRX | 0 | $0 | 9,643 | $184,200 | 4,000 | $8,320 |
| 2021 | PLRX | 0 | $0 | 0 | $0 | 40,000 | $83,200 |
| 2020 | PLRX | 0 | $0 | 18,734 | $553,777 | 42,534 | $127,250 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-17 | PLRX | Sale | 20,148 | 11.20 | 225,677 |
| 2024-07-10 | PLRX | Sale | 10,911 | 11.56 | 126,131 |
| 2024-05-02 | PLRX | Option Ex | 21,000 | 2.08 | 43,680 |
| 2024-01-17 | PLRX | Sale | 9,781 | 17.23 | 168,526 |
| 2023-07-17 | PLRX | Sale | 19,771 | 18.01 | 356,055 |
| 2023-06-13 | PLRX | Option Ex | 30,750 | 2.08 | 63,960 |
| 2023-06-09 | PLRX | Option Ex | 5,800 | 2.08 | 12,064 |
| 2023-03-30 | PLRX | Sale | 9,960 | 26.52 | 264,149 |
| 2023-01-23 | PLRX | Sale | 30,000 | 35.00 | 1,050,000 |
| 2023-01-23 | PLRX | Option Ex | 30,000 | 4.15 | 124,500 |
| 2022-12-22 | PLRX | Option Ex | 4,000 | 2.08 | 8,320 |
| 2022-12-20 | PLRX | Sale | 9,643 | 19.10 | 184,200 |
| 2021-09-03 | PLRX | Option Ex | 20,000 | 2.08 | 41,600 |
| 2021-03-05 | PLRX | Option Ex | 20,000 | 2.08 | 41,600 |
| 2020-12-21 | PLRX | Option Ex | 4,500 | 2.08 | 9,360 |
| 2020-12-01 | PLRX | Option Ex | 18,734 | 4.15 | 77,746 |
| 2020-12-01 | PLRX | Sale | 18,734 | 29.56 | 553,777 |
| 2020-04-30 | PLRX | Option Ex | 19,300 | 2.08 | 40,144 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Cummings Keith Lamont (Chief Financial Officer of Pliant Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.